Boehringer Ingelheim’s SENVELGO gets EU marketing authorization for feline diabetes treatment
The European Commission has granted marketing authorization to Boehringer Ingelheim for SENVELGO (active ingredient: velagliflozin), a groundbreaking development in the treatment of feline diabetes across ... Read More